Playlist


A high-level meeting took place in Ashgabat between the leadership of the Turkmennebit State Concern and a visiting delegation from Malaysia, led by the Chairman of the Consultative Committee on Political Affairs under the Prime Minister. The discussions focused on enhancing bilateral ties within the fuel and energy sectors. Both parties reviewed the success of ongoing operations and expressed a shared commitment to deepening their long-term strategic alliance.
The hallmark of the meeting was the official signing ceremony of a Protocol regarding the commercial terms of the existing Production Sharing Agreement (PSA) between Turkmennebit and PETRONAS Carigali. This formal agreement updates the economic frameworks governing their joint ventures, ensuring that both entities benefit from the latest developments in global energy markets. The protocol serves as a critical roadmap for future investment and operational growth.
During the dialogue, the participants emphasized the importance of utilizing the full potential of Turkmen-Malaysian cooperation in the hydrocarbon industry. Representatives from Malaysia reaffirmed their dedication to contributing advanced technological expertise to Turkmenistan's energy infrastructure. The collaboration is expected to focus on increasing extraction efficiency and exploring new opportunities within the offshore and onshore sectors.
This renewed agreement underscores the stability and transparency of Turkmenistan's investment climate for major international energy corporations. The partnership between Turkmennebit and PETRONAS continues to be a cornerstone of the nation’s industrial strategy, promoting economic diversification and technological exchange. Both sides expressed optimism that this protocol will pave the way for even more ambitious projects in the coming years.
Also read


American researchers have initiated trials for a new pharmaceutical compound designated as ENV-308, designed to replicate the physiological effects of intensive physical training. Formulated in tablet form, the medication aims to trigger the body's metabolic responses similar to those experienced during exercise.
Scientists at Enveda utilized the Lac-Phe molecule as the core component for this development. Naturally produced by the body during vigorous exertion, this molecule transmits signals to the brain that suppress appetite and signal satiety.
Preclinical trials conducted on animal models demonstrated significant positive results. The tablets effectively reduced hunger levels and facilitated weight loss while entirely preserving existing muscle mass.
Researchers have successfully completed the first phase of clinical trials, confirming the safety of the drug for human use. Future studies will focus on evaluating the compound's impact on metabolism and exploring its potential combination with established therapeutics such as Ozempic.